[go: up one dir, main page]

MX2007004549A - Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico. - Google Patents

Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico.

Info

Publication number
MX2007004549A
MX2007004549A MX2007004549A MX2007004549A MX2007004549A MX 2007004549 A MX2007004549 A MX 2007004549A MX 2007004549 A MX2007004549 A MX 2007004549A MX 2007004549 A MX2007004549 A MX 2007004549A MX 2007004549 A MX2007004549 A MX 2007004549A
Authority
MX
Mexico
Prior art keywords
kinase inhibitor
bortezomib
growth factor
factor receptor
epidermal growth
Prior art date
Application number
MX2007004549A
Other languages
English (en)
Inventor
Bilal Piperdi
Original Assignee
Bilal Piperdi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bilal Piperdi filed Critical Bilal Piperdi
Publication of MX2007004549A publication Critical patent/MX2007004549A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion proporciona un metodo para fabricar un medicamento destinado para tratar tumores o metastasis tumorales en un paciente, caracterizado porque se utiliza una cantidad terapeuticamente efectiva de un inhibidor de la cinasa de EGFR y bortezomib, con o sin agentes adicionales o tratamientos, tales como otros farmacos anticancerosos o terapia con radiacion. La invencion tambien abarca una composicion farmaceutica que esta comprendida de una combinacion del inhibidor de la cinasa de EGFR y el bortezomib, en combinacion con un portador farmaceuticamente aceptable. Un ejemplo preferido de un inhibidor de la cinasa de EGFR que puede ser utilizado en la practica de esta invencion, es el compuesto clorhidrato de erlotinib (tambien conocido como TarcevaMR).
MX2007004549A 2004-10-18 2005-10-18 Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico. MX2007004549A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61984404P 2004-10-18 2004-10-18
PCT/US2005/037324 WO2006110175A2 (en) 2004-10-18 2005-10-18 Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2007004549A true MX2007004549A (es) 2007-07-11

Family

ID=36922148

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004549A MX2007004549A (es) 2004-10-18 2005-10-18 Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico.

Country Status (11)

Country Link
US (1) US20060084691A1 (es)
EP (1) EP1804809A2 (es)
JP (1) JP2008516983A (es)
KR (1) KR20070083719A (es)
CN (1) CN101043892A (es)
AU (1) AU2005330507A1 (es)
BR (1) BRPI0517104A (es)
CA (1) CA2583520A1 (es)
IL (1) IL182584A0 (es)
MX (1) MX2007004549A (es)
WO (1) WO2006110175A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012256A1 (en) 2003-07-22 2005-02-10 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
AU2005249201A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with irinotecan (CPT-11) and an EGFR-inhibitor
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) * 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
WO2007146226A2 (en) * 2006-06-09 2007-12-21 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
AU2008239594B2 (en) 2007-04-13 2013-10-24 Beth Israel Deaconess Medical Center Methods for treating cancer resistant to ErbB therapeutics
WO2010022277A2 (en) * 2008-08-20 2010-02-25 O'connor Owen A Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers
WO2010039762A2 (en) * 2008-10-01 2010-04-08 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising boronic acid compounds
WO2010057048A1 (en) * 2008-11-13 2010-05-20 Calistoga Pharmaceuticals Inc. Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
RU2529800C2 (ru) * 2010-03-18 2014-09-27 ИННОФАРМА, Инк. Стабильные составы бортезомиба
US20130211384A1 (en) * 2010-07-28 2013-08-15 Fondazione Irccs Istituto Nazionale Dei Tumori Therapeutic agent, composition including said agent, implantable device and process for the treatment of cervical cancer and/or for the prevention of the formation of neoplasms in correspondence of the cervix in a human female genital system
ES2655642T3 (es) * 2011-05-16 2018-02-21 Ulrike Nuber Terapias contra el cáncer novedosas y métodos
KR101695237B1 (ko) * 2013-10-11 2017-01-12 이화여자대학교 산학협력단 보르테조밉을 유효성분으로 함유하는 간독성 질환의 예방 및 치료용 조성물
WO2016179306A1 (en) * 2015-05-05 2016-11-10 The Regents Of The University Of California Improved drug combinations for drug-resistant and drug-sensitive multiple myeloma
WO2019169389A1 (en) * 2018-03-02 2019-09-06 Epicentrx, Inc. Methods and compositions for treating cancer and sensitizing tumor cells to kinase inhibitors
BR112021006407A8 (pt) * 2018-10-04 2022-12-06 Inst Nat Sante Rech Med uso de inibidores do egfr para ceratodermas
KR102825542B1 (ko) 2020-12-10 2025-06-26 주식회사 엘지화학 보론산 화합물
KR20220118247A (ko) 2021-02-18 2022-08-25 김성운 커트용 헤어빗
WO2025199602A1 (pt) * 2024-03-28 2025-10-02 Instituto Butantan Composição farmacêutica compreendendo mitógenos e inibidores de vias de controle de estresse para o tratamento de câncer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0201480A3 (en) * 1999-05-14 2009-03-30 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US20040167139A1 (en) * 2002-07-26 2004-08-26 Potter David A. Methods of treating cancer

Also Published As

Publication number Publication date
WO2006110175A3 (en) 2007-03-08
BRPI0517104A (pt) 2008-09-30
CN101043892A (zh) 2007-09-26
KR20070083719A (ko) 2007-08-24
CA2583520A1 (en) 2006-10-19
AU2005330507A1 (en) 2006-10-19
WO2006110175A9 (en) 2006-11-23
JP2008516983A (ja) 2008-05-22
WO2006110175A2 (en) 2006-10-19
EP1804809A2 (en) 2007-07-11
US20060084691A1 (en) 2006-04-20
IL182584A0 (en) 2008-04-13

Similar Documents

Publication Publication Date Title
MX2007004549A (es) Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
WO2007106503A3 (en) Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
WO2007075554A3 (en) Combination of igfr inhibitor and anti-cancer agent
NO20066056L (no) Behandling med Gemcitabin og en EGFR-inhibitor
MX2007009960A (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
WO2009008992A3 (en) Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
AU2014248377B2 (en) Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
WO2006110176A3 (en) Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
NO20066054L (no) behandling med cisplatin og en EGFR-inhibitor
TW200603804A (en) Treatment with irinotecan (cpt-11) and an EGFR-inhibitor
CA2514227A1 (en) Combination therapy of zd6474 with 5-fu or/and cpt-11
IL164564A0 (en) Combination therapy for the treatment of cancer
WO2009073139A3 (en) Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit
MX2024006168A (es) Composicion farmaceutica y uso de la misma.
TW200608959A (en) Treatment with oxaliplatin and an egfr-inhibitor
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
MX2007006927A (es) Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer.
Vokes Current treatments and promising investigations in a multidisciplinary setting
MXPA04009012A (es) Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer.
EA200901145A1 (ru) Применение рибофлавина в лечении гипертензии
TH84265A (th) การรักษาด้วยอิริโนทีแคน (cpt-11) และสารยับยั้ง egfr
TNSN08512A1 (en) Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists
Vokes Symposium article Current treatments and promising investigations in a multidisciplinary setting
US20160367553A1 (en) Methods and Compositions for Treating Cancers having Acquired Resitance to prior Chemotherapeutic and Targeted Drugs Using Carboxyamidotriazole Orotate

Legal Events

Date Code Title Description
FA Abandonment or withdrawal